Emerging agents for the therapy of advanced prostate cancer
| Autor: | Guru Sonpavde, Mary K. Baker, Amanda Redden Hathaway |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents chemistry.chemical_compound Prostate cancer Internal medicine medicine Enzalutamide Humans Predictive biomarker Androgen inhibitor business.industry Abiraterone acetate General Medicine Immunotherapy Cytotoxic chemotherapy medicine.disease Prostatic Neoplasms Castration-Resistant chemistry Cabazitaxel business medicine.drug |
| Zdroj: | Future oncology (London, England). 11(20) |
| ISSN: | 1744-8301 |
| Popis: | Since 2010, multiple advances have been made in the field of metastatic castration-resistant prostate cancer including regulatory approvals for five new agents including androgen pathway inhibitors (enzalutamide, abiraterone acetate), immunotherapy (sipuleucel-T), cytotoxic chemotherapy (cabazitaxel) and radiopharmaceuticals (radium-223) that have improved overall survival in this patient population. Despite these advances, each therapy has only extended median survival by 3–5 months and data suggest substantial cross-resistance among them. Given these modest increments, there is a major role for the vigorous investigation of new drugs and predictive biomarkers to select suitable patients who will benefit from them. This review describes emerging promising agents and their ongoing clinical development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|